Zoetis Publishes Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported a 5% decline in companion animal revenue and a 7% drop in adjusted net income for Q3, with gross margin compression. While some segments like diagnostics and livestock grew, the overall earnings pressure led to a stock price drop. The company is working to offset declines with its product pipeline.

Zoetis reported US livestock revenue of $266M for Q3 2026, up 5% YoY, driven by cattle, swine, and poultry. Worldwide livestock revenue rose 7% to $797M, with international sales up 8%.

Zoetis (ZTS) reported Q3 2026 results with revenue and adjusted net income declining as expected. The company narrowed its 2026 revenue outlook to $9.22B-$9.32B and raised adjusted EPS guidance to $6.25-$6.35. CEO Kristin Peck noted challenging dynamics persist.

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

Zoetis reported better-than-expected Q3 results and raised its 2026 adjusted earnings forecast, but shares fell 7% due to a cautious 2027 outlook. The company cited rising veterinary costs and competition, leading to a 3% drop in US clinic visits and pressure on dermatology sales. CEO Kristin Peck noted increased affordability concerns among pet owners.

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.